India plans to introduce incentives to boost domestic production of GLP-1 drugs by 2026, primarily used to treat diabetes and obesity. Originally approved for diabetes management, GLP-1 drugs like semaglutide, found in popular medications such as Wegovy and Ozempic, are now acknowledged for aiding weight loss by slowing down digestion. As the patent for Novo Nordisk’s semaglutide expires in India in 2026, local pharmaceutical companies have applied for the government’s production-linked incentive (PLI) scheme. Mr. Arunish Chawla, Secretary of the Department of Pharmaceuticals, affirmed that these companies will receive incentives once they commence manufacturing after the patent’s expiration.
The market potential for anti-obesity medications is significant, with Goldman Sachs Research predicting it could grow to US$ 100 billion by 2030. In India, Sun Pharmaceutical Industries Ltd. is advancing its weight-loss formulation, while Cipla Ltd. and Dr. Reddy’s Laboratories Ltd. are focused on developing generic drugs for weight management. India faces rising obesity rates exacerbated by increased consumption of unhealthy foods, highlighting the critical need for effective treatments.
